Also known as glutamate pyruvate transaminase, ALT, and GPT.
Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
Semaglutide 2.4 mg improves liver health in MASH patients, showing benefits across weight loss levels and diverse demographics, according to ESSENCE trial data.
